FAP expression in deep and superficial endometriosis: Association with MRI and transvaginal ultrasound visibility
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8727-8738
DOI: 10.1007/s00259-026-08189-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 18.09.2026. Verfasst von Keiko Akashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Endometriosis, Magnetic Resonance Imaging, Membrane Proteins, Gelatinases. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Mayo Clinic.
Abstract (Originalsprache)
PURPOSE: Fibroblast activation protein (FAP) is expressed in the fibroinflammatory stroma of endometriosis, but its relationship to conventional imaging visibility is unknown. We evaluated FAP expression in deep endometriosis (DE) and superficial endometriosis (SE) and its relationship to lesion visibility on magnetic resonance imaging (MRI) and transvaginal ultrasound (TVUS). METHODS: We retrospectively analyzed specimens from DE (n = 13) and SE (n = 9) patients who underwent MRI and/or TVUS. FAP expression was assessed immunohistochemically using H-scores. Two abdominal radiologists independently graded the visibility of pathology-confirmed lesions on MRI and TVUS using a study-specific 0-3 scale, with N/A assigned when the lesion location was outside the available imaging field of view. H-scores were compared by phenotype and imaging visibility (lower [0-1] vs higher [2-3]) using nonparametric analyses. RESULTS: FAP expression did not differ significantly between DE and SE (median H-scores 170 vs 200, p= 0.738). Endometriosis showed substantial FAP expression, although H-scores were lower than colorectal adenocarcinoma controls (p 0.05). On TVUS, 1 and 2 lesions were assigned N/A for Readers 1 and 2, respectively; among evaluable lesions, low-/high-visibility groups included 2/10 and 1/10 lesions, with median H-scores of 48/165 and 20/160, respectively, limiting conclusions regarding visibility and FAP expression. CONCLUSION: DE and SE showed substantial stromal FAP expression, including SE lesions poorly visible on conventional imaging. These findings provide a histopathological rationale for FAP-targeted imaging in endometriosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Mayo Clinic, Rochester, MN, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
- Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
- Department of Radiology, Mayo Clinic, Rochester, MN, USA. Takahashi.Hiroaki@mayo.edu.
Förderung
- Mayo Clinic
Zitieren
APA
Akashi, K., Shahi, M., Colak, C., Burnett, T. L., Bartlett, D. J., Packard, A. T., VanBuren, W. M., & Takahashi, H. (2026). FAP expression in deep and superficial endometriosis: Association with MRI and transvaginal ultrasound visibility. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8727-8738. https://doi.org/10.1007/s00259-026-08189-3
Vancouver
Akashi K, Shahi M, Colak C, Burnett TL, Bartlett DJ, Packard AT, et al. FAP expression in deep and superficial endometriosis: Association with MRI and transvaginal ultrasound visibility. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8727-8738. doi:10.1007/s00259-026-08189-3
BibTeX
@article{Akashi2026,
author = {Akashi, Keiko and Shahi, Maryam and Colak, Ceylan and Burnett, Tatnai L and Bartlett, David J and Packard, Annie T and VanBuren, Wendaline M and Takahashi, Hiroaki},
title = {FAP expression in deep and superficial endometriosis: Association with MRI and transvaginal ultrasound visibility},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8727--8738},
doi = {10.1007/s00259-026-08189-3}
}
EUVIMED